Substitution of factor XIII: a therapeutic approach to ulcerative colitis.
Three patients with ulcerative colitis in the active stage demonstrated reduced levels of F XIII activity and F XIII subunit A (61 and 80.3%, respectively). Because of the lack of clinical improvement during conservative therapy, the patients were treated additionally with F XIII concentrate (Fibrogammin HS, Behring, FRG) for 10 days. The substitution resulted in an increase in F XIII activity (144.3%) and F XIII subunit A (238%) as well as in a marked improvement in symptoms.
Lorenz
R
R
II. Medizinische Klinik und Poliklinik, Technischen Universität München, FRG.
Heinmüller
M
M
Classen
M
M
Tornieporth
N
N
Gain
T
T
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D001778:Blood Coagulation Disorders / Q000097:blood / Q000209:etiology / Q000628:therapy*; D003093:Colitis, Ulcerative / Q000150:complications* / Q000188:drug therapy; D005176:Factor XIII / Q000032:analysis / Q000627:therapeutic use*; D005177:Factor XIII Deficiency; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000209:etiology / Q000628:therapy*; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D008875:Middle Aged; D012460:Sulfasalazine / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D008795:Metronidazole; D012460:Sulfasalazine; D005176:Factor XIII